B cell phenotype after rituximab in TTP patients

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2249|179|3|414-425

ISSN： 0009-9104

Source： CLINICAL & EXPERIMENTAL IMMUNOLOGY, Vol.179, Iss.3, 2015-03, pp. : 414-425

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

High Ki67 Index and Bulky Disease Remain Significant Adverse Prognostic Factors in Patients with Diffuse Large B Cell Lymphoma before and after the Introduction of Rituximab

By  

Acta Haematologica, Vol. 126, Iss. 1, 2011-03 ,pp. : 44-51

Karger

Access to resources Recommend Favorite

Long‐term remission of recurrent thrombotic thrombocytopenic purpura (TTP) after Rituximab in children and young adults

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 5, 2015-05 ,pp. : 823-829

John Wiley & Sons Inc

Access to resources Recommend Favorite

Successful Treatment of Pure Red Cell Aplasia with Rituximab in Patients after ABO-Compatible Allogeneic Hematopoietic Stem Cell Transplantation

By  

Case Reports in Oncology, Vol. 5, Iss. 1, 2012-02 ,pp. : 110-113

Karger

Access to resources Recommend Favorite

Response to Rituximab and Timeframe to Relapse in Rheumatoid Arthritis Patients: Association with B-Cell Markers

By Pyrpasopoulou Athina  

Molecular Diagnosis & Therapy, Vol. 14, Iss. 1, 2010-02 ,pp. : 43-48

Adis International

Access to resources Recommend Favorite

Serum rituximab levels and efficiency of B cell depletion: differences between patients with rheumatoid arthritis and systemic lupus erythematosus

By Reddy Venkat  

British Journal of Rheumatology , Vol. 52, Iss. 5, 2013-05 ,pp. : 951-952

Oxford University Press

Access to resources Recommend Favorite